Rashna Khanna
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Migraine and Headache Studies, Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Cardiovascular Syncope and Autonomic Disorders, Amyloidosis: Diagnosis, Treatment, Outcomes
Most-Cited Works
- → Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease(2018)1,031 cited
- → Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)(2019)98 cited
- → Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials(2019)88 cited
- → Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease(2025)77 cited
- → Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction(2025)35 cited
- → Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine(2021)18 cited
- → Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies(2021)17 cited
- → Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study(2020)15 cited
- → Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan(2020)12 cited
- → Safety profile of lasmiditan in patients with migraine in an Asian population(2022)8 cited